Making clinical trials truly representative of the disease populations they target is not an effort confined solely to the U.S. and FDA; it is a global initiative with many considerations that differ by country, culture and regulatory agency. The CenterWatch Monthly interviewed Liz Beatty, cofounder and chief strategy officer at Inato, a tech provider focused on boosting trial inclusivity and access around the world, to discuss thinking from an international perspective on diversity, equity and inclusion (DE&I).
